Head-To-Head Analysis: Intellia Therapeutics (NTLA) versus The Competition

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Intellia Therapeutics to similar companies based on the strength of its profitability, valuation, institutional ownership, risk, dividends, analyst recommendations and earnings.

Insider & Institutional Ownership

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Intellia Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intellia Therapeutics -805.75% -64.74% -50.72%
Intellia Therapeutics Competitors -12,224.75% -204.85% -31.52%

Risk & Volatility

Intellia Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Intellia Therapeutics’ competitors have a beta of -1.86, indicating that their average share price is 286% less volatile than the S&P 500.

Valuation & Earnings

This table compares Intellia Therapeutics and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intellia Therapeutics $67.67 million -$412.69 million -2.91
Intellia Therapeutics Competitors $690.30 million $8.55 million -18.43

Intellia Therapeutics’ competitors have higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Intellia Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics 4 7 9 1 2.33
Intellia Therapeutics Competitors 9941 15335 45756 1605 2.54

Intellia Therapeutics presently has a consensus target price of $21.44, suggesting a potential upside of 119.61%. As a group, “Biotechnology” companies have a potential upside of 134.32%. Given Intellia Therapeutics’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics has less favorable growth aspects than its competitors.

Summary

Intellia Therapeutics competitors beat Intellia Therapeutics on 7 of the 13 factors compared.

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.